Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy (Q37135388)

18 August 2017

1 reference

title

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy (English)

1 reference

18 August 2017

1 reference

R Simó

1

1 reference

PubMed ID

18404258

18 August 2017

C Hernández

series ordinal

2

1 reference

18 August 2017

11 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

51

1 reference

18 August 2017

1574-1580

1 reference

18 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-008-0989-9

18 August 2017

0 references

cites work

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-0989-9

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-0989-9

Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-0989-9

Treatment of diabetic foot ulcer: an overview strategies for clinical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-0989-9

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-0989-9

Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-0989-9

The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

21 January 2018

1 reference

12 December 2020

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

1 reference

12 December 2020

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

12 December 2020

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

1 reference

12 December 2020

Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population

1 reference

12 December 2020

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

1 reference

12 December 2020

Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab

1 reference

12 December 2020

Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model

1 reference

12 December 2020

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

1 reference

12 December 2020

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.

1 reference

12 December 2020

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.

1 reference

12 December 2020

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

1 reference

12 December 2020

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

12 December 2020

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

1 reference

12 December 2020

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

12 December 2020

The epidemiology of lower extremity amputations in diabetic individuals

1 reference

12 December 2020

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

1 reference

12 December 2020

Drug delivery systems for vitreoretinal diseases

1 reference

12 December 2020

Important Causes of Visual Impairment in the World Today

1 reference

12 December 2020

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

1 reference

12 December 2020

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years

1 reference

12 December 2020

Vascular endothelial cell growth factor-a: not just for endothelial cells anymore.

1 reference

12 December 2020

Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.

1 reference

12 December 2020

Developing aptamers into therapeutics

1 reference

12 December 2020

Pegaptanib for neovascular age-related macular degeneration

1 reference

12 December 2020

Wound healing and its impairment in the diabetic foot

1 reference

12 December 2020

Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

1 reference

12 December 2020

Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells

1 reference

12 December 2020

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

12 December 2020

Role of vascular endothelial growth factor in regulation of physiological angiogenesis

1 reference

12 December 2020

Ranibizumab for neovascular age-related macular degeneration

1 reference

12 December 2020

Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells

1 reference

12 December 2020

Effect of anti-VEGF antibody on retinal ganglion cells in rats.

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

1 reference

12 December 2020

Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy

1 reference

12 December 2020

Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice

1 reference

12 December 2020

Intravitreal avastin: the low cost alternative to lucentis?

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

1 reference

12 December 2020

Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue

1 reference

12 December 2020

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

12 December 2020

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

1 reference

12 December 2020

Economic costs of diabetes in the US in 2002.

1 reference

12 December 2020

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

1 reference

12 December 2020

Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing

1 reference

12 December 2020

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

1 reference

12 December 2020

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.

1 reference

12 December 2020

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

12 December 2020

Association of macular involvement with proliferative retinopathy in Type 2 diabetes

1 reference

12 December 2020

VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells

1 reference

12 December 2020

Incidence of end-stage renal disease among persons with diabetes--United States, 1990-2002.

1 reference

12 December 2020

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

1 reference

12 December 2020

10.1007/S00125-008-0989-9

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18404258